Eiger BioPharmaceuticals, Inc. 4/A
4/A · Eiger BioPharmaceuticals, Inc. · Filed Sep 15, 2016
Insider Transaction Report
Form 4/AAmended
Martins Eduardo Bruno
SVP, Liver and Infectious Dise
Transactions
- Award
Stock Option (Right to Buy)
2016-03-23+65,216→ 65,216 totalExercise: $15.89Exp: 2026-03-23→ Common Stock (65,216 underlying)
Footnotes (2)
- [F1]The option will vest as to 25% of the option shares on November 1, 2016 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
- [F2]The option grant was approved by Issuer's board of directors on March 22, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016.